OGECHI EJIGIRI: Open Payments
NPI 1689070013 · GREENSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$461 in 32 payments from 10 companies in 2025. Trend: 2023 $231 · 2024 $539 · 2025 $461
Food & beverage: $461
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $180 |
| Novo Nordisk Inc | 3 | $57 |
| Calliditas Therapeutics US Inc. | 2 | $56 |
| Travere Therapeutics, Inc. | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Alexion Pharmaceuticals, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
Products named: Fabhalta, Ozempic, TARPEYO, ULTOMIRIS, IBSRELA, JARDIANCE, SHINGRIX, VELPHORO.
Industry payments across NC — which companies pay providers there.
